Apellis Pharmaceuticals Achieves Profitability in 2025 with Strong Revenue Growth and Strategic Deals
Summary
Apellis Pharmaceuticals achieved net income of $22.4 million in 2025, a significant turnaround from previous losses, driven by strong total revenue growth and a major upfront payment from a Sobi royalty agreement, despite a European regulatory setback for SYFOVRE.
Key Events
-
Achieved Net Income in 2025
The company reported a net income of $22.4 million for the year ended December 31, 2025, a significant improvement from net losses of $197.9 million in 2024 and $528.6 million in 2023.
-
Strong Total Revenue Growth
Total revenue increased to $1,003.8 million in 2025, up from $781.4 million in 2024, primarily due to a substantial increase in licensing and other revenue.
-
Significant Sobi Royalty Buy-Down Payment
Apellis received a $275.0 million upfront payment from Sobi under a Royalty Buy-Down Agreement in July 2025, with an additional $25.0 million milestone received in February 2026 following EMA approval of Aspaveli for C3G and primary IC-MPGN.
-
EMPAVELI Approved for New Indications
The FDA approved EMPAVELI for the treatment of C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (primary IC-MPGN) in July 2025, and pivotal trials for FSGS and DGF were initiated in Q4 2025.
Analysis
Apellis Pharmaceuticals reported a significant financial turnaround in 2025, achieving a net income of $22.4 million, a substantial improvement from net losses in prior years. This shift was primarily driven by a robust increase in total revenue to over $1 billion, significantly boosted by a $275.0 million upfront payment from a Royalty Buy-Down Agreement with Sobi. The company also saw continued product development progress, including FDA approval for EMPAVELI in C3G and primary IC-MPGN, and positive 5-year data for SYFOVRE. However, the European Commission's rejection of SYFOVRE's marketing authorization application in December 2024 presents a notable setback for international expansion. Additionally, $93.9 million in convertible notes are now classified as current liabilities, requiring attention in the near term. Despite these challenges, the overall financial performance marks a critical positive inflection point for the company.
At the time of this filing, APLS was trading at $22.44 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.8B. The 52-week trading range was $16.10 to $30.48. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.